Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 07, 2023

BUY
$64.85 - $71.7 $696,294 - $769,842
10,737 New
10,737 $727,000
Q1 2023

May 01, 2023

SELL
$63.15 - $71.6 $414,137 - $469,552
-6,558 Reduced 92.37%
542 $37,000
Q4 2022

Feb 07, 2023

SELL
$54.21 - $70.44 $81,315 - $105,660
-1,500 Reduced 17.44%
7,100 $481,000
Q3 2022

Oct 25, 2022

SELL
$53.02 - $135.75 $106,040 - $271,500
-2,000 Reduced 18.87%
8,600 $471,000
Q2 2022

Aug 04, 2022

BUY
$59.26 - $71.14 $74,075 - $88,925
1,250 Added 13.37%
10,600 $700,000
Q1 2022

Apr 14, 2022

BUY
$55.72 - $67.12 $50,148 - $60,408
900 Added 10.65%
9,350 $620,000
Q4 2021

Jan 18, 2022

SELL
$54.02 - $63.83 $152,768 - $180,511
-2,828 Reduced 25.08%
8,450 $492,000
Q3 2021

Oct 26, 2021

BUY
$55.56 - $60.79 $338,638 - $370,515
6,095 Added 117.6%
11,278 $677,000
Q2 2021

Jul 19, 2021

BUY
$48.42 - $60.18 $250,960 - $311,912
5,183 New
5,183 $310,000
Q3 2020

Oct 27, 2020

SELL
$53.07 - $61.1 $37,149 - $42,770
-700 Closed
0 $0
Q2 2020

Jul 22, 2020

BUY
$43.1 - $55.31 $30,170 - $38,717
700 New
700 $37,000
Q1 2019

May 10, 2019

SELL
$35.49 - $43.02 $322,533 - $390,965
-9,088 Closed
0 $0
Q4 2018

Feb 05, 2019

SELL
$36.86 - $41.49 $11,058 - $12,447
-300 Reduced 3.2%
9,088 $345,000
Q3 2018

Nov 07, 2018

BUY
$34.76 - $39.72 $232,892 - $266,124
6,700 Added 249.26%
9,388 $371,000
Q2 2018

Aug 10, 2018

SELL
$34.55 - $37.05 $13,819 - $14,819
-400 Reduced 12.95%
2,688 $94,000
Q1 2018

May 11, 2018

BUY
$32.97 - $36.63 $79,128 - $87,912
2,400 Added 348.84%
3,088 $107,000
Q4 2017

Jan 17, 2018

SELL
$32.09 - $34.78 $45,311 - $49,109
-1,412 Reduced 67.24%
688 $23,000
Q3 2017

Oct 17, 2017

BUY
$28.96 - $34.0 $60,816 - $71,400
2,100
2,100 $71,000

Others Institutions Holding AZN

About ASTRAZENECA PLC


  • Ticker AZN
  • Exchange OTC
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 3,099,020,032
  • Market Cap $200B
  • Description
  • AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...
More about AZN
Track This Portfolio

Track Cutler Group LP Portfolio

Follow Cutler Group LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

News

Stay updated on Cutler Group LP with notifications on news.